Scientific Background: Serine 129 is the C-terminal serine characteristic to mammalian alpha synuclein, with this serine being determined to be a major phosphorylation site (1). Lewy Bodies in Parkinson’s Disease (PD) and other related synucleinopathies are comprised of alpha synuclein phosphorylated at serine 129 and this phosphorylation may contribute to an increased propensity to aggregate (2). Due to phosphorylation at serine 129 being one of the most abundant PTMs, several studies reported on the PTM as a potential biomarker (3). Our Alpha Synuclein Ser129 Monomers are generated in-house and phosphorylation confirmed with our anti-ASYN pS129 monoclonal antibody (Catalog# SMC-600).
References: 1. Okochi et al. 2000. Constitutive phosphorylation of the Parkinson’s Disease Associated a-Synuclein. The Journal of Biological Chemistry. DOI: 10.1074/jbc.275.1.3902. Fujiwara et al. 2002. α-Synuclein is phosphorylated in synucleinopathy lesions. Nature Cell Biology. DOI: 10.1038/ncb7483. Magalhaes and Lashuel. 2002. Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson’s disease and other synucleinopathies. Npj Parkinsons Disease. DOI: 10.1038/s41531-022-00357-0
Field of Use: Not for use in humans. Not for use in diagnostics or therapeutics. For research use only.